XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
- Mechanism
- Curator reviewed
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Code names
- XL019
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with XL019, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account